-
Notifications
You must be signed in to change notification settings - Fork 0
/
Copy pathreferences.txt
16 lines (9 loc) · 1.92 KB
/
references.txt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1. Birzu, C., French, P., Caccese, M., Cerretti, G., Idbaih, A., Zagonel, V., & Lombardi, G. (2020). Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers, 13(1), 47.
2. Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors
Ajit J. Nirmal, Tim Regan, Barbara B. Shih, David A. Hume, Andrew H. Sims and Tom C. Freeman Cancer Immunol Res November 1 2018 (6) (11) 1388-1400; DOI: 10.1158/2326-6066.CIR-18-0342
3. Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., ... & Suvà, M. L. (2019). An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell, 178(4), 835-849.
4. Aibar S, Bravo Gonzalez-Blas C, Moerman T, Huynh-Thu V, Imrichova H, Hulselmans G, Rambow F, Marine J, Geurts P, Aerts J, van den Oord J, Kalender Atak Z, Wouters J, Aerts S (2017). “SCENIC: Single-Cell Regulatory Network Inference And Clustering.” Nature Methods, 14, 1083-1086.
5. Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., ... & Prins, R. M. (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature medicine, 25(3), 477-486.
6. Ruiz-Moreno, C., Salas, S. M., Samuelsson, E., Brandner, S., Kranendonk, M. E., Nilsson, M., & Stunnenberg, H. G. (2022). Harmonized single-cell landscape, intercellular crosstalk and tumor architecture of glioblastoma. bioRxiv.
7. Garofano, L., Migliozzi, S., Oh, Y. T., D’Angelo, F., Najac, R. D., Ko, A., ... & Iavarone, A. (2021). Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nature cancer, 2(2), 141-156.
8. Yan, K., Lu, Y., Yan, Z., & Wang, Y. (2021). 9-Gene Signature Correlated With CD8+ T Cell Infiltration Activated by IFN-γ: A Biomarker of Immune Checkpoint Therapy Response in Melanoma. Frontiers in immunology, 2223.